BioInvent International AB (SE0015244520) — research page
SE · se-cm-kg/XSTO/SE0015244520 · as of 2026-11-06
Identity and listing
The issuer is BioInvent International AB, listed on Nasdaq Stockholm under the ticker SE0015244520 with ISIN SE0015244520 and LEI 549300E7QRHEF2IJUY10. The security type, segment, sector and jurisdiction are not on the record. The listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | BioInvent International AB | source · 2026-11-06 |
| exchange | Nasdaq Stockholm | source · 2026-11-06 |
| ticker | SE0015244520 | source · 2026-11-06 |
| ISIN | SE0015244520 | source · 2026-11-06 |
| LEI | 549300E7QRHEF2IJUY10 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 39 filings in the twelve months to 2026-11-06, on 32 filing days. The median gap between filing days is 8 days. The latest filing is 1 day before the record date, and its date is 2026-11-05, of type Inside information. The exchange median gap between filing days is 9.5 days, the exchange median is 30.0 filings and the exchange median latency is 7.0 days, across 398 issuers on Nasdaq Stockholm. The sector comparison is not on the record.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 39 | 8 | 1 |
| exchange median: Nasdaq Stockholm (398 issuers) | 30 | 9.5 | 7 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-05 | Inside information | Inside information | BioInvent announces final terms for the Rights Issue of approximately SEK 430 million and informs that the Issue is fully guaranteed by additional top guarantee undertakings |
| 2026-10-30 | Notice to general meeting | Notice to general meeting | Supplement: Notice to Extraordinary General Meeting in BioInvent International AB |
| 2026-10-28 | Notice to general meeting | Notice to general meeting | Notice to Extraordinary General Meeting in BioInvent International AB |
| 2026-10-28 | Interim report (Q1 and Q3) | Interim report (Q1 and Q3) | BioInvent International AB: Interim report January - September, 2026 |
| 2026-10-28 | Inside information | Inside information | BioInvent resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January - September 2026 |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is not on the record, and neither is its location. The market's record does not carry auditor changes.
Events and halts
The record carries no listing, delisting, name change, domicile change or segment move lines, because the lifecycle type map for this market is not yet on the register. The issuer is listed, not halted.
Orderability
The outcome is not determinable for this issuer. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.
rule acm-68000/se/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's investor-relations page names 4 research houses: Pareto Securities, Zurich; Kempen, Amsterdam; Redeye, Stockholm; and DNB Carnegie, Stockholm.
| research house | analyst | source · read date |
|---|---|---|
| Pareto Securities, Zurich | Chien-Hsun Lee | issuer page · 2026-11-12 |
| Kempen, Amsterdam | Sebastiaan van der Schoot | issuer page · 2026-11-12 |
| Redeye, Stockholm | Richard Ramanius | issuer page · 2026-11-12 |
| DNB Carnegie, Stockholm | Arvid Necander | issuer page · 2026-11-12 |
Open research
No openly published research notes were found on the record.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No sealed years hold the issuer, no earliest sealed date is given for the market, and the live record began on no date given.
Sources
7 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.se-cm-kg.ai/events/XSTO/SE0015244520 (the disclosure lines)
- 10.4
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)
- 10.5
- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://www.bioinvent.com/en/investors/analysts (coverage)
- 10.7
- https://mcp.se-cm-kg.ai/record/XSTO/SE0015244520 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"SE0015244520"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:21f70d6b5796ab16.